IDO1 and nasopharyngeal carcinoma: While BTZ downregulates IFN-γ-induced IDO expression in nasopharyngeal carcinoma cells, it restores IDO1 protein levels in DCs from non-obese diabetic mice by inhibiting proteasomal degradation.